Half-life extension through albumin fusion technologies (Q39746766)

14 September 2017

title

Half-life extension through albumin fusion technologies (English)

1 reference

14 September 2017

Stefan Schulte

1

1 reference

14 September 2017

publication date

1 December 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

124 Suppl 2

1 reference

14 September 2017

page(s)

S6-8

1 reference

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Strategies towards a longer acting factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Progress in the molecular biology of inherited bleeding disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Development of a long-acting insulin analog using albumin fusion technology

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Prolonged in-vivo half-life of factor VIIa by fusion to albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970157-4

7 January 2021

10.1016/S0049-3848(09)70157-4

Identifiers

DOI

1 reference

14 September 2017

1 reference